investors.f-star.com Open in urlscan Pro
2a02:26f0:6c00::210:ba8a  Public Scan

Form analysis
3 forms found in the DOM

GET /search

<form data-block-uuid="3107b8f1-a110-49ec-a0b9-c85d55de5e6f" action="/search" method="get" accept-charset="UTF-8">
  <div class="js-form-item form-item js-form-type-search form-item-query js-form-item-query form-no-label">
    <input type="search" name="query" size="60" maxlength="128" placeholder="Search.." class="form-search required" required="required" aria-required="true">
  </div>
  <input type="submit" name="op" value="Search" class="button button--primary js-form-submit form-submit">
</form>

GET /search

<form data-block-uuid="3107b8f1-a110-49ec-a0b9-c85d55de5e6f" action="/search" method="get" accept-charset="UTF-8">
  <div class="js-form-item form-item js-form-type-search form-item-query js-form-item-query form-no-label">
    <input type="search" name="query" size="60" maxlength="128" placeholder="Search.." class="form-search required" required="required" aria-required="true">
  </div>
  <input type="submit" name="op" value="Search" class="button button--primary js-form-submit form-submit">
</form>

/ir-resources#row-white2

<form action="/ir-resources#row-white2" class="ndq-footer-alerts" id="alerts-form">
  <div class="embed-submit-field"><label class="hidden" for="nir_email_alerts_signup_email">Request Email Alerts</label> <input aria-label="Request Email Alerts" id="nir_email_alerts_signup_email" name="nir_email_alerts_signup_email"
      placeholder="Request Email Alerts" type="email"><button aria-label="submit form" type="submit">→</button></div>
</form>

Text Content

Skip to main navigation
 * About
   * Leadership
   * Board of Directors
   * Pharmaceutical Partnerships
   * Meet F-Star Team Members
 * Technology
   * Our Platform
   * Publications
   * Intellectual Property
 * Pipeline
   * FS118
   * FS120
   * FS222
   * SB 11285
   * Partnerships
 * Investors
 * Careers
 * News
 * Contact Us

×

 * Careers
 * Investors

 * About
   * Leadership
   * Board of Directors
   * Pharmaceutical Partnerships
   * Meet F-Star Team Members
 * Technology
   * Our Platform
   * Publications
   * Intellectual Property
 * Pipeline
   * FS118
   * FS120
   * FS222
   * SB 11285
 * Contact




INVESTORS


 * Overview
 * Press Releases
 * Events & Presentations

 * Stock Information
 * SEC Filings
 * Analyst Coverage

 * Annual Shareholder Meeting
 * Governance
 * IR Resources


 * Navigate
    * Overview
    * Press Releases
    * Events & Presentations
   
    * Stock Information
    * SEC Filings
    * Analyst Coverage
   
    * Annual Shareholder Meeting
    * Governance
    * IR Resources




CORPORATE PROFILE

F-star is a clinical-stage immuno-oncology company focused on transforming the
lives of patients with cancer through the development of F-star’s innovative
tetravalent mAb2 bispecific antibodies.

With four distinct binding sites in a natural human antibody format, F-star
believes its proprietary technology will overcome many of the challenges facing
current immuno-oncology therapies, because of the strong pharmacology enabled by
tetravalent bispecific binding.

F-star’s vision is to transform the treatment of cancer through the development
of clinically differentiated and well tolerated mAb2 bispecific antibodies,
which are designed to address multiple immune evasion pathways that limit the
effect of current immuno-oncology therapies.

F-star’s leadership team has decades of combined experience in pharma and
biotech. Together they have successfully brought 20 drugs to market.


STOCK INFORMATION

NASDAQ CM: FSTX
$6.01 +0.0896 (+1.51%)


Data Provided by Refinitiv. Minimum 15 minutes delayed.


PRESS RELEASES

 * Aug 11, 2022
   
   F-star Therapeutics Reports Second Quarter 2022 Financial Results and
   Corporate Highlights

 * Aug 04, 2022
   
   invoX Pharma Extends Tender Offer to Acquire F-star Therapeutics, Inc.

 * Jul 20, 2022
   
   F-star Therapeutics Announces a License Agreement with Takeda for a Novel
   Next-Generation Immuno-oncology Bispecific Antibody



View More


EVENTS

 * May 10, 2022 at 9:00 AM EDT
   
   F-Star Therapeutics First Quarter 2022 Earnings Call

 * Apr 8, 2022
   
   F-star Therapeutics Presents a Novel LAG-3 Reduction and Shedding Mechanism
   with FS118 at AACR 2022

 * Mar 15, 2022 at 2:40 PM EDT
   
   32nd Annual Oppenheimer Healthcare Conference



View More

Corporate Presentation

Download

STOCK INFORMATION

Learn More

INFORMATION REQUEST

Learn More

FINANCIALS

Learn More

GOVERNANCE

Learn More

 * Investor Contact
 * RSS
 * Print Page

Request Email Alerts →

About

 * Overview
 * Leadership
 * Board of Directors
 * Pharmaceutical Partnerships

Technology

 * Overview
 * Our Platform
 * Publications
 * Intellectual Property

Pipeline

 * Program Overview
 * FS118
 * FS120
 * FS222
 * SB 11285

 

 * Investors
 * Careers
 * News
 * Contact Us

 * About
   * Leadership
   * Board of Directors
   * Pharmaceutical Partnerships
   * Meet F-Star Team Members
 * Technology
   * Our Platform
   * Publications
   * Intellectual Property
 * Pipeline
   * FS118
   * FS120
   * FS222
   * SB 11285
   * Partnerships
 * Investors
 * Careers
 * News
 * Contact Us

 * 
 * 



Eddeva B920
Babraham Research
CampusCambridge, CB22 3AT, UK

245 First Street
Riverview II, Floor 18
Cambridge, MA 02142, USA

 * Disclaimer
 * Privacy Policy
 * Cookie Policy
 * Careers
 * Sitemap

© 2022 F-star Therapeutics, Inc.